Inter partes

Former Administrative Patent Judge and Associate Solicitor Kristi L.R. Sawert, Ph.D., Joins Fish & Richardson, Expanding Post-Grant Practice and Life Science Focus

Retrieved on: 
Monday, January 22, 2024
Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Other Science, Other Technology, Medical Devices, Research, Legal, Science, Intellectual property, Biochemistry, House, Professional, Internet, Biology, Heart, Associate, Patent, Justice, Policy, Multimedia, Chemistry, Knowledge, The Honourable, Berea College, Government, Computer, Inter partes, PTE, Supreme court, PTAB, Doctor of Philosophy, Ohio State University, Fish & Richardson, Pharmaceutical industry

Today former U.S. Patent Trial and Appeal Board Administrative Patent Judge and Associate Solicitor Kristi L.R.

Key Points: 
  • Today former U.S. Patent Trial and Appeal Board Administrative Patent Judge and Associate Solicitor Kristi L.R.
  • As a principal, Dr. Sawert will focus her experience on representing life sciences clients, particularly in biotechnology and pharmaceuticals.
  • “Kristi brings a rare and valuable combination of law firm and government experience to Fish,” said John Adkisson, Fish president & chief executive officer.
  • “During my tenure as an administrative patent judge, I had the opportunity to see firsthand the impressive professionalism, preparedness, and skill of Fish attorneys,” said Sawert.

Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents

Retrieved on: 
Friday, May 19, 2023
Software, Research, Professional Services, Pharmaceutical, Technology, Genetics, Health Technology, Science, Legal, Chemicals, Plastics, Biotechnology, Health, Manufacturing, Patent, IPR, United States Court of Appeals for the Federal Circuit, Stanford University, Guide, PTAB, RNA, Trademark, Agilent Technologies, Inter partes, NYSE, Fine chemical, CRISPR

Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board’s (PTAB) Final Written Decision in connection with the Inter Partes review (IPR) of U.S. Patent Nos.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board’s (PTAB) Final Written Decision in connection with the Inter Partes review (IPR) of U.S. Patent Nos.
  • The PTAB recently reversed the USPTO’s original decision granting claims directed towards chemically modified synthetic CRISPR guide RNA.
  • The Agilent Patents describe synthesis and testing of hundreds of chemically modified CRISPR guide RNA molecules that were shown to improve the efficiency of CRISPR-based gene editing.
  • The PTAB’s decision in no way affects Agilent’s ability to make or sell chemically modified gRNA guides.

Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review

Retrieved on: 
Tuesday, July 26, 2022
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Inter partes, Patent Trial and Appeal Board, EGFR, 1836 U.S. Patent Office fire, Sun Pharma, CEO, Patent, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Adult, NASDAQ, PTAB, IPR, Review, FDA, Company, Patient, Lupus nephritis, USPTO, Pharmaceutical industry, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial on the Inter Partes review (IPR) filed by Sun Pharmaceuticals, directed at U.S. Patent No.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial on the Inter Partes review (IPR) filed by Sun Pharmaceuticals, directed at U.S. Patent No.
  • While this decision is disappointing, as we have stated from the start of his process, we will vigorously defend this patent, said Peter Greenleaf, President and CEO, Aurinia Pharmaceuticals.
  • This patent already had significant review at the USPTO before being approved as being a valid patent by that office and we are fully prepared to continue legal proceedings to protect our intellectual property.
  • 10,286,036 was issued to Aurinia in support of the unique eGFR pharmacodynamic dosing protocol used within the Companys clinical trials, and extends patent protection for LUPKYNIS to 2037.

Thorne Research, Inc., Continues to Challenge the Validity of U.S. Patents on Nicotinamide Riboside

Retrieved on: 
Thursday, February 4, 2021
ChromaDex, United States patent law, Nicotinamide riboside, Inter partes review, Inter partes, Patent

8,197,807, which relates to compositions of nicotinamide riboside for oral administration.

Key Points: 
  • 8,197,807, which relates to compositions of nicotinamide riboside for oral administration.
  • 8,197,807 is Dartmouth College, which has licensed the patent's rights to ChromaDex, Inc.
    U.S. Patent No.
  • Thorne Research's petition for inter partes review uses a different legal strategy to challenge the claims.
  • Thorne is the leader in providing medical practitioners, athletes, and consumers with innovative health solutions of the highest quality and caliber.

Argentum Pharmaceuticals and Bausch Health Settle Patent Dispute Over JUBLIA®

Retrieved on: 
Wednesday, January 13, 2021
Inter partes review, Patent, Efinaconazole, Inter partes, United States patent law

NEW YORK, Jan. 13, 2021 /PRNewswire/ --Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced that it has reached a settlement agreement with Bausch Health US, LLC and Kaken Pharmaceutical Co., LTD., related to Argentum's inter partes review petition challenging an Orange Book-listed patent for JUBLIA (efinaconazole) Topical Solution.

Key Points: 
  • NEW YORK, Jan. 13, 2021 /PRNewswire/ --Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced that it has reached a settlement agreement with Bausch Health US, LLC and Kaken Pharmaceutical Co., LTD., related to Argentum's inter partes review petition challenging an Orange Book-listed patent for JUBLIA (efinaconazole) Topical Solution.
  • Argentum filed its IPR petition against U.S. Patent 7,214,506 (the "506 Patent") onMay 12, 2017.
  • On January 8th, 2021 the Patent Trial & Appeal Board granted the parties joint motion to terminate the IPR.
  • The patent that was being challenged by Argentum (U.S. Patent No.

Liquidia Provides Update on U.S. Patent Trial and Appeal Board Decision on Inter Partes Review of Two United Therapeutics’ Tyvaso® Patents

Retrieved on: 
Wednesday, October 14, 2020
United States patent law, Inter partes review, PTAB, United Therapeutics, Inter partes

9,604,901 (901) and concurrently denied institution on 9,593,066 (066), both owned by United Therapeutics Corporation (UTC) and listed in the Orange Book for Tyvaso (treprostinil).

Key Points: 
  • 9,604,901 (901) and concurrently denied institution on 9,593,066 (066), both owned by United Therapeutics Corporation (UTC) and listed in the Orange Book for Tyvaso (treprostinil).
  • For 901, the PTAB Institution Decision states that based on the information presented, we institute an inter partes review of claims 19 of the 901 patent.
  • Mr. Fowler added, The Liquidia management team and our board are committed to providing PAH patients with alternative treatment options, like LIQ861, that we believe they need and deserve.
  • In July, UTC filed an amended complaint asserting infringement of an additional recently issued U.S. Patent No.

NajingTech's lawsuit against Nanosys halted after U.S. Patent Office questions validity of U.S. Patent No. 7,105,051

Retrieved on: 
Tuesday, September 1, 2020
Intellectual property law, United States patent law, Inter partes review, Nanosys, United States Patent and Trademark Office, Patent, Inter partes

Silicon Valley-based Nanosys has worked hard over the past two decades to create a vibrant, growing marketplace for its proprietary quantum dot technology.

Key Points: 
  • Silicon Valley-based Nanosys has worked hard over the past two decades to create a vibrant, growing marketplace for its proprietary quantum dot technology.
  • On August 25, 2020, the trial court brought this lawsuit to a halt because the U.S. Patent Office had decided to review the validity of the '051 patent.
  • In particular, on August 18, 2020, the Patent Office instituted an Inter Partes Review of the '051 patent, which is special proceeding for the Office to assess the validity of issued patents.
  • In instituting this proceeding, the Patent Office found that Nanosys "has established a reasonable likelihood of prevailing in showing that claims 111 and 1323 of the '051 patent are unpatentable."

Gogo Files Petition to Challenge Validity of SmartSky Patent

Retrieved on: 
Wednesday, April 1, 2020
Intellectual property law, United States patent law, Intellectual property organizations, Inter partes, Gogo Business Aviation, Go go, United States Patent and Trademark Office, Patent, SAS Institute Inc. v. Iancu

BROOMFIELD, Colo., April 1, 2020 /PRNewswire/ --Gogo Business Aviation (NASDAQ: GOGO) has submitted a petition to the U.S. Patent and Trademark Office requesting an inter partes review of U.S. Patent No.

Key Points: 
  • BROOMFIELD, Colo., April 1, 2020 /PRNewswire/ --Gogo Business Aviation (NASDAQ: GOGO) has submitted a petition to the U.S. Patent and Trademark Office requesting an inter partes review of U.S. Patent No.
  • 9,312,947 ("the '947 patent") granted to SmartSky Networks, LLC.
  • An inter partes review re-examines the claims in a patent to determine whether or not they are valid.
  • "We strongly believe that the '947 patent granted to SmartSky is not valid," said Sergio Aguirre, president Gogo Business Aviation.

Fish & Richardson Named Most Active Law Firm at Patent Trial and Appeal Board for Fourth Consecutive Year

Retrieved on: 
Monday, March 9, 2020
Intellectual property law, United States patent law, Article I tribunals, United States Patent and Trademark Office, Fish & Richardson, Patent Trial and Appeal Board, PTAB, IPR, Inter partes, Lex Machina

BOSTON, March 9, 2020 /PRNewswire/ -- Fish & Richardson has been named the most active law firm at the Patent Trial and Appeal Board (PTAB) for the fourth consecutive year according to a recent Lex Machina report that analyzedinter partes (IPR) reviews challenges filed in 2019.

Key Points: 
  • BOSTON, March 9, 2020 /PRNewswire/ -- Fish & Richardson has been named the most active law firm at the Patent Trial and Appeal Board (PTAB) for the fourth consecutive year according to a recent Lex Machina report that analyzedinter partes (IPR) reviews challenges filed in 2019.
  • Fish had more appearances than any other firm appearing in a total of 116 IPRs in 2019.
  • Since the inception of post-grant proceedings in 2012, Fish has appeared in 1,138 proceedings, far exceeding its closest competitor at the PTAB.
  • Fish & Richardson, the premier global intellectual property law firm, is trusted by the world's most innovative and influential companies.

PTAB Bounces Challenge to Trampoline Arena Patent Announces Haley Guiliano LLP

Retrieved on: 
Friday, May 24, 2019
United States patent law, Inter partes review, Patent Trial and Appeal Board, PTAB, Inter partes, Patent

SAN JOSE, Calif., May 24, 2019 /PRNewswire/ -- Haley Guiliano LLP announces the Patent Trial and Appeal Board today declined to Institute Inter Partes Review on a Petition challenging U.S. Patent No.

Key Points: 
  • SAN JOSE, Calif., May 24, 2019 /PRNewswire/ -- Haley Guiliano LLP announces the Patent Trial and Appeal Board today declined to Institute Inter Partes Review on a Petition challenging U.S. Patent No.
  • The '575 Patent was filed in 2010 by Marcus Gurley, the founder of Rebounderz trampoline arenas out of Sanford, FL.
  • At the time of Mr. Gurley's patent application filing only a few trampoline arenas existed in the world.
  • Haley Guiliano LLP represents Rebounderz in its district court cases and before the PTAB.